Comorbidities in inflammatory joint and spine diseases in XXI century


Cite item

Full Text

Abstract

Progress and significant changes in the approaches to the diagnosis and treatment of arthritis determine the need for a comprehensive study of comorbidities in rheumatologic patients. Aim. The evaluation the occurrence of comorbidities in patients with inflammatory diseases of the spine and joints and the assessment of the general changes in comorbidities at the beginning of the XXI century compared to previous period. Materials and methods. Comorbidity was analyzed in 245 patients with spondyloarthritis who participated in the scientific program PROGRESS. Validated comorbidity assessment indices were used in the study. The analysis of 96 sources of literary bases RISC and PubMed were used in literature analysis. The results of their own observation and literary search were compared. Results and discussion. According to the patients’ cards, an analysis of the structure of comorbidities was conducted in 221 patients: 207 (93.66%) patients with spondyloarthritis had two or more comorbidities. The most common diseases were diseases of gastrointestinal tract (60.6%) and cardiovascular pathology (58.3%), secondary osteoarthritis (60.2%). According to literature sources, most of the comorbidities and spondyloarthritis are interrelated pathogenetically and undergo a change in the profile of rheumatic and/or related diseases undergo simultaneous changes. The emergence of new diseases in the structure of comorbidity and new drugs requires the development of recommendations that take into account the presence of comorbidity in patients with a rheumatic diseases. Conclusion. Most patients with spondyloarthritis has comorbidity. The change in rheumatic and non-rheumatic diseases that occurs in the 21st century has a mutual influence, changing the profile of patients and determining the change in the tactics of their management.

About the authors

I Z Gaydukova

I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation

Email: ubp1976@list.ru
д.м.н., проф. каф. терапии, ревматологии, экспертизы временной нетрудоспособности и оценки качества медицинской помощи им. Э.Э. Эйхвальда СЗГМУ им. И.И. Мечникова Saint-Petersburg, Russia

A I Akulova

V.I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation

к.м.н., ассистент каф. госпитальной терапии лечебного факультета СГМУ им. В.И. Разумовского Saratov, Russia

A P Rebrov

V.I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation

д.м.н., проф., зав. каф. госпитальной терапии лечебного факультета СГМУ им. В.И. Разумовского Saratov, Russia

References

  1. Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe H.J. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int. 2017;114(12):197-203. doi: 10.3238/arztebl.2017.0197
  2. Van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman R.D, Jongkees M, Kiltz U, Kvien T.K, Machado P.M, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos F.M, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016-210770
  3. Schoels M.M, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien T.K, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen J.S, Wit Md, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat - to - target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860
  4. Wendling D. Treating to target in axial spondyloarthritis: defining the target and the arrow. Expert Rev Clin Immunol. 2015 Jun;11(6):691-3. doi: 10.1586/1744666X.2015.1039514
  5. Pinheiro F.A, Souza D.C, Sato E.I. A Study of Multiple Causes of Death in Rheumatoid Arthritis. J Rheumatol. 2015;42(12):2221-8. doi: 10.3899/jrheum.150166
  6. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;23:357,j2099. doi: 10.1136/bmj.j2099
  7. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maître M, Ortonne J.P, Paul C, Richard M.A.Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013 Aug;27(Suppl 3):12-29. doi: 10.1111/jdv.12163
  8. Hartl A, Sieper J, Syrbe U, Listing J, Hermann K.G, Rudwaleit M, Poddubnyy D. Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Res Ther. 2017;19(1):140. doi: 10.1186/s13075-017-1350-9
  9. Fallahi S. Relationship of smoking quantity with outcome measures in patients with ankylosing spondylitis: Comments on the article by Villaverde-García V. et al. Semin Arthritis Rheum. 2017. pii: S0049-0172(17)30175-0. doi: 10.1016/j.semarthrit.2017.03.011
  10. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou C.T, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan M.A, Kirazli Y, Maksymowych W.P, Mielants H, Sørensen I.J, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J.The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83. doi: 10.1136/ard.2009.108233
  11. Garrett S, Jenkinson T, Kennedy L.G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
  12. Van der Heijde D, Lie E, Kvien T.K, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Dec;68(12):1811-8. doi: 10.1136/ard.2008.100826
  13. Machado P, Landewé R, Lie E, Kvien T.K, Braun J, Baker D, van der Heijde D; Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut - off values for disease activitystates and improvement scores. Ann Rheum Dis. 2011 Jan;70(1):47-53. doi: 10.1136/ard.2010.138594
  14. Calin A, Garrett S, Whitelock H, Kennedy L.G, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-5.
  15. Charlson M.E, Pompei P, Ales K.L, Mac Kenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
  16. Kaplan M.H, Feinstein A.R. The importance of classifying initial co - morbidity in evaluating the outcome of diabetes mellitus. J Chron Dis. 1974;27(7-8):387-404.
  17. Conwell Y, Forbes N.T, Cox C, Caine E.D. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc. 1993;41(1):38-41.
  18. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002
  19. Bengtsson K, Forsblad -d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, Lindström U, Askling J, Jacobsson LTH. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population - based cohort study. Arthritis Res Ther. 2017;19(1):102. doi: 10.1186/s13075-017-1315-z
  20. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, Burgos-Vargas R, Cheung P.P, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim T.H, Kishimoto M, Luo S.F, Machado P.M, Maksymowych W.P, Maldonado-Cocco J, Marzo-Ortega H, Montecucco C.M, Ozgoçmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross - sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016;75(6):1016-23. doi: 10.1136/annrheumdis-2015-208174
  21. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch M.H, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo S.F, Kurucz R, Maciel G, Mola E.M, Montecucco C.M, McInnes I, Radner H, Smolen J.S, Song Y.W, Vonkeman H.E, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross - sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223
  22. Van Doornum S, Bohensky M, Tacey M.A, Brand C.A, Sundararajan V, Wicks I.P. Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease. Arthritis Res Ther. 2015;17:38. doi: 10.1186/s13075-015-0552-2
  23. Подряднова М.В., Эрдес Ш.Ф., Дубинина Т.В., Старкова А.С., Красненко С.О., Урумова М.М., Агафонова Е.М., Балабанова Р.М. Мультиморбидность анкилозирующего спондилита - результаты российского исследования, проведенного в рамках международной программы COMOSPA. Научно - практическая ревматология. 2016;54(S1):123-4
  24. Yen Y.F, Jen I.A, Chen M, Lan Y.C, Lee C.Y, Chuang P.H, Lee Y, Arthur Chen Y.M. Human Immunodeficiency Virus Infection Increases the Risk of Incident Psoriasis: A Nationwide Population - based Cohort Study in Taiwan. J Acquir Immune Defic Syndr. 2017. doi: 10.1097/QAI.0000000000001431
  25. Bardazzi F, Magnano M, Campanati A, Loconsole F, Carpentieri A, Potenza C, Bernardini N, Di Lernia V, Carrera C, Raone B, Patrizi A, Loi C. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Derm Venereol. 2017. doi: 10.2340/00015555-2698
  26. Fink D.L, Hedley L, Miller R.F. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals. Int J STD AIDS. 2017;28(2):110-9. doi: 10.1177/0956462416675109
  27. Dey A.K, Joshi A.A, Chaturvedi A, Lerman J.B, Aberra T.M, Rodante J.A, Teague H.L, Harrington C.L, Rivers J.P, Chung J.H, Kabbany M.T, Natarajan B, Silverman J.I, Ng Q, Sanda G.E, Sorokin A.V, Baumer Y, Gerson E, Prussick R.B, Ehrlich A, Green L.J, Lockshin B.N, Ahlman M.A, Playford M.P, Gelfand J.M, Mehta N.N. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiol. 2017. doi: 10.1001/jamacardio.2017.1213

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies